Core Points - The company announced that its board member and secretary, Ms. Liang Shujie, plans to reduce her shareholding by selling up to 375,189 shares, which represents approximately 0.0365% of the total share capital [2] - The reduction plan was disclosed on September 18, 2025, and has now been completed [2] Summary by Category Shareholding Reduction - Ms. Liang Shujie holds a total of 1,500,759 shares, accounting for 0.1461% of the company's total shares [2] - The planned reduction will occur within three months following the announcement, specifically through centralized bidding [2] Implementation Status - The company has received a notification from Ms. Liang Shujie confirming the completion of the share reduction plan [2]

Core Viewpoint - The announcement from Shuanglu Pharmaceutical indicates that the planned share reduction by the board secretary has been completed without affecting the company's control [1] Group 1: Share Reduction Details - The board secretary, Liang Shujie, planned to reduce holdings by up to 375,189 shares, representing no more than 0.0365% of the total share capital [1] - The actual reduction was completed with a total of 375,090 shares sold at an average price of 7.5454 yuan per share [1] - Post-reduction, Liang Shujie's holdings decreased to 1,125,669 shares, which is 0.1096% of the total share capital [1] Group 2: Compliance and Control - The share reduction complies with relevant regulations and does not lead to a change in the company's control [1]

Group 1 - The core viewpoint of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant advancement in biotechnology and organ transplantation [1] - The first clinical trial was completed at NYU Langone Medical Center, approved by the FDA, aiming to evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - Global advancements in gene editing technology have been reported, including successful transplantation of gene-edited pig lungs in China and new treatment approaches for Down syndrome in Japan [1] Group 2 - Huazhong Securities highlights that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production of drugs [2] - In the A-share market, there are 22 listed companies with gene editing technology reserves, with mixed performance in stock prices; only 7 out of 22 companies saw gains on November 5 [4] - Among gene editing concept stocks, Shuanglu Pharmaceutical reported the highest net profit of 141 million yuan in the first three quarters, while Mengcao Ecological achieved a year-on-year profit increase of 48.73% [5][6] Group 3 - Eight gene editing concept stocks received attention from five or more institutions, with companies like Sturdy Medical and Huaxi Biological leading in institutional ratings [7] - Sturdy Medical announced a collaboration with Huazhong Agricultural University to establish a cotton research institute, focusing on gene editing and hybridization techniques for cotton seed improvement [7]

Group 1 - The core point of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant breakthrough in gene editing technology [1] - The trials are approved by the FDA and aim to systematically evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - There have been multiple advancements in gene editing technology globally, including successful transplants of gene-edited organs and new treatment approaches for genetic disorders [1] Group 2 - Huazhong Securities notes that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production and reducing drug production costs [2] - A total of 22 listed companies in the A-share market have gene editing technology reserves, with several companies reporting profitability in their third-quarter results [3] - Notable companies include Shuanglu Pharmaceutical, which reported a net profit of 141 million yuan, and Mengcao Ecological, which saw a 48.73% year-on-year increase in net profit [3][4] Group 3 - Companies like Wanjian Medical are collaborating with research institutions to develop cotton varieties using gene editing technology, indicating the application of gene editing beyond human health [5] - The number of institutional ratings for gene editing concept stocks shows significant interest, with companies like Wanjian Medical and Huaxi Biological receiving the highest number of ratings [6]

Core Viewpoint - The company, Shuanglu Pharmaceutical, expressed its openness to welcoming various outstanding professional managers to join the organization [2] Group 1 - Shuanglu Pharmaceutical responded to investor inquiries on November 3, indicating its continuous interest in attracting talented managerial professionals [2]

Core Viewpoint - The company, Shuanglu Pharmaceutical, emphasizes the importance of comprehensive project evaluation and plans to enhance market promotion and sales team development [1] Group 1 - The company will conduct a comprehensive assessment of its projects [1] - There will be an increase in investment in market promotion [1] - The company aims to strengthen its sales team [1]

Core Viewpoint - The major shareholders of Shuanglu Pharmaceutical are not involved in the securities lending business [2] Group 1 - Shuanglu Pharmaceutical responded to investor inquiries on November 3 regarding the involvement of its major shareholders in securities lending [2]

Core Viewpoint - The review of the long-acting follicle-stimulating hormone has been suspended due to reaching the review deadline, and the company is currently awaiting supplementary comments [1] Company Summary - 双鹭药业 (Shuanglu Pharmaceutical) has communicated with investors regarding the status of its long-acting follicle-stimulating hormone review process [1]

Core Viewpoint - As of September 30, 2025, the total number of shareholders for Shuanglu Pharmaceutical is reported to be 54,779 [2] Company Summary - Shuanglu Pharmaceutical responded to investor inquiries on November 3, indicating the total number of shareholders [2]

Group 1 - The company Shuanglu Pharmaceutical announced on November 3 that its adenosylmethionine has been successfully awarded a bid [2] - The planned bidding regions include Shandong, Hubei, Tianjin, Shanxi, and Ningxia [2]